About tlcr

Manuscript Submission

AME Editing Service

Reprint & Permission

Advertising

Contact us

Sponsored by

Translational Lung Cancer Research is sponsored by General Hospital of Eastern Theater Command, Nanjing, China

Sponsored by

Consensus

Tubeless video-assisted thoracic surgery for pulmonary ground-glass nodules: expert consensus and protocol (Guangzhou)
Jianxing He, Hengrui Liang, Wei Wang, Andrey Akopov, Alberto Aiolfi, Keng-Leong Ang, Luca Bertolaccini, Kaican Cai, Qingdong Cao, Baojun Chen, Chang Chen, Chun Chen, Donglai Chen, Fengxia Chen, Jun Chen, Lei Chen, Mingwu Chen, Yongbing Chen, Zhuxing Chen, Chao Cheng, Dong Cui, Fei Cui, Tianyang Dai, Qinglong Dong, Paolo A. Ferrari, Raja M. Flores, Junke Fu, Soichiro Funaki, Marios E. Froudarakis, Xiangfeng Gan, Mingfei Geng, Jialong Guo, Qiang Guo, Yongtao Han, Jintao He, Kaiming He, Kyoji Hirai, Jian Hu, Shuqiao Hu, Jian Huang, Jun Huang, Wenfa Jiang, Kyung Soo Kim, Gabor Kiss, Fanyi Kong, Lan Lan, Xuefeng Leng, Bin Li, Gaofeng Li, Hecheng Li, Hefei Li, Heng Li, Jiwei Li, Xiaoqiang Li, Shuben Li, Yinfen Li, Zhuoyi Li, Yi Liang, Lixia Liang, Wenhua Liang, Yongde Liao, Wanli Lin, Xu Lin, Hongxu Liu, Hui Liu, Jixian Liu, Jun Liu, Xiang Liu, Zihao Liu, Xingzhao Lu, Qingquan Luo, Naiquan Mao, Qi Pan, Dazhi Pang, Jun Peng, Jun Peng, Eugenio Pompeo, Rulin Qian, Kun Qiao, Bassam Redwan, Zi Sang, Wenlong Shao, Jianfei Shen, Weiyu Shen, Sook-Whan Sung, Wenfang Tang, Tianhu Wang, Guangsuo Wang, Haitao Wang, Huien Wang, Jiyong Wang, Wen Wang, Yongyong Wang, Zhenyuan Wang, Li Wei, Wei Wei, Hao Wu, Jie Wu, Zhaohua Xia, Chenyang Xu, Enwu Xu, Hai Xu, Ning Xu, Quan Xu, Rongyu Xu, Shun Xu, Chaokun Yang, Hanyu Yang, Shengli Yang, Jun Yi, Guangjian Zhang, Hao Zhang, Jia Zhang, Man Zhang, Xiao Zhang, Yajie Zhang, Zhe Zhang, Zhifeng Zhang, Honglin Zhao, Jian Zhao, Xiaodong Zhao, Jianping Zhou, Yanran Zhou, Chengchu Zhu, Shaojin Zhu, Xinhai Zhu, Jian Cui, Yubo Yan, Ke-Neng Chen

Original Article

An analysis of the immunological tumor microenvironment of primary tumors and regional lymph nodes in squamous cell lung cancer
Yoshinobu Ichiki, Mari Ueno, Shinya Yanagi, Yoshiro Kanasaki, Hidenori Goto, Takashi Fukuyama, Shuji Mikami, Kozo Nakanishi, Tsuyoshi Ishida
Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study
Konstantinos Rounis, Dimitrios Makrakis, Alexandros-Pantelis Tsigkas, Alexandra Georgiou, Nikolaos Galanakis, Chara Papadaki, Alexia Monastirioti, Lambros Vamvakas, Konstantinos Kalbakis, Nikolaos Vardakis, Meropi Kontogianni, Ioannis Gioulbasanis, Dimitrios Mavroudis, Sofia Agelaki
The best regimens for chemo-naïve incurable non-squamous non- small cell lung cancer with a programmed death-ligand 1, tumor proportion score 1–49%: a network meta-analysis
Nobuhiko Fukuda, Nobuyuki Horita, Seigo Katakura, Ho Namkoong, Ayami Kaneko, Kouhei Somekawa, Youichi Tagami, Keisuke Watanabe, Yu Hara, Nobuaki Kobayashi, Takeshi Kaneko
Interactions between epidermal growth factor receptor tyrosine kinase inhibitors and proton-pump inhibitors/histamine type-2 receptor antagonists in non-small cell lung cancer: a systematic review and meta-analysis
Wilson Sim, Sneha Rajiv Jain, Wen Hui Lim, Yip Han Chin, Cheng Han Ng, Nicholas Syn, Kang Shiong Goh, Ross Soo, Lingzhi Wang, Boon Cher Goh
Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study
Akihiro Yoshimura, Tadaaki Yamada, Yusuke Okuma, Akito Fukuda, Satoshi Watanabe, Naoya Nishioka, Takayuki Takeda, Yusuke Chihara, Shinnosuke Takemoto, Taishi Harada, Osamu Hiranuma, Yukina Shirai, Akihiro Nishiyama, Seiji Yano, Yasuhiro Goto, Shinsuke Shiotsu, Kei Kunimasa, Yoshie Morimoto, Masahiro Iwasaku, Yoshiko Kaneko, Junji Uchino, Hirotsugu Kenmotsu, Toshiaki Takahashi, Koichi Takayama
The Chinese Thoracic Oncology Group (CTONG) therapeutic option scoring system: a multiple-parameter framework to assess the value of lung cancer treatment options
Jiu-Wei Cui, Qing Zhou, Shun Lu, Ying Cheng, Jie Wang, Ri-Lan Bai, Wen-Qian Li, Lei Qian, Xiao-Yuan Chen, Yun Fan, Cheng Huang, Xiao-Qing Liu, Hai-Yan Tu, Jin-Ji Yang, Li Zhang, Jian-Ying Zhou, Wen-Zhao Zhong, Yi-Long Wu; on behalf of the Chinese Thoracic Oncology Group (CTONG)
Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a STK11 mutation
Josiah An, Melissa Yan, Nanmeng Yu, Adithya Chennamadhavuni, Muhammad Furqan, Sarah L. Mott, Bradley T. Loeffler, Timothy Kruser, Timothy L. Sita, Lawrence Feldman, Ryan Nguyen, Mary Pasquinelli, Nasser H. Hanna, Taher Abu Hejleh
A nomogram for preoperative prediction of prolonged air leak after pulmonary malignancy resection
Runsen Jin, Yuyan Zheng, Taotao Gao, Yajie Zhang, Bingshun Wang, Junbiao Hang, Hecheng Li
Endovascular steerable and endobronchial precurved guiding sheaths for transbronchial needle delivery under augmented fluoroscopy and cone beam CT image guidance
Quirina M. B. de Ruiter, Joseph R. Fontana, William F. Pritchard, Michal Mauda-Havakuk, Ivane Bakhutashvili, Juan A. Esparza-Trujillo, Nicole A. Varble, Marco Verstege, Sheng Xu, Reza Seifabadi, Robert F. Browning, Bradford J. Wood, John W. Karanian
Surgical mediastinal lymph node staging for non-small-cell lung carcinoma
Pieter W. J. Lozekoot, Jean H. T. Daemen, Robert R. van den Broek, Jos G. Maessen, Michiel H. M. Gronenschild, Yvonne L. J. Vissers, Karel W. E. Hulsewé, Erik R. de Loos
Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study
Takamasa Koga, Kenichi Suda, Masaya Nishino, Toshio Fujino, Shuta Ohara, Akira Hamada, Junichi Soh, Vijaya Tirunagaru, Avanish Vellanki, Robert C. Doebele, Tetsuya Mitsudomi
Use of diffusion-weighted magnetic resonance imaging (DW-MRI) to predict early response to anti-tumor therapy in advanced non-small cell lung cancer (NSCLC): a comparison of intravoxel incoherent motion-derived parameters and apparent diffusion coefficient
Zheng Yuan, Xiao-Min Niu, Xue-Mei Liu, Hong-Chao Fu, Ting-Jia Xue, Chi Wan Koo, Katsuhiro Okuda, Feng Yao, Xiao-Dan Ye

Review Article

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future
Bryan A. Chan, Brett G.M. Hughes
Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer
Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto
Global trends of lung cancer mortality and smoking prevalence
Farhad Islami, Lindsey A. Torre, Ahmedin Jemal
Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review
Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao
Tackling ALK in non-small cell lung cancer: the role of novel inhibitors
Francesco Facchinetti, Marcello Tiseo, Massimo Di Maio, Paolo Graziano, Emilio Bria, Giulio Rossi, Silvia Novello
Circulating tumor cells versus circulating tumor DNA in lung cancer—which one will win?
Silvia Calabuig-Fariñas, Eloísa Jantus-Lewintre, Alejandro Herreros-Pomares, Carlos Camps

Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities
Jeryl Villadolid, Asim Amin

Original Article

Prognostic value of Twist in lung cancer: systematic review and meta-analysis
Junli Zeng, Ping Zhan, Guannan Wu, Wen Yang, Wenjun Liang, Tangfeng Lv, Yong Song
BRAF mutations in non-small cell lung cancer
Peter P. Luk, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina Selinger, Trina Lum, Steven Kao, Sandra A. O’Toole, Wendy A. Cooper
The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer
Shu Wang, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina I. Selinger, Sandra A. O’Toole, Wendy A. Cooper
Itraconazole can inhibit malignant pleural effusion by suppressing lymphangiogenesis in mice
Yunfen Wang, Yanwen Yao, Hongbin Liu, Xingqun Ma, Tangfeng Lv, Dongmei Yuan, Xinwu Xiao, Jie Yin, Yong Song
Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer
Fangfang Chen, Yanwen Yao, Chunyan Ma, Xingqun Ma, Zhaofeng Wang, Tangfeng Lv, Xinwu Xiao, Jie Yin, Yong Song
Advanced proton beam dosimetry part II: Monte Carlo vs. pencil beam-based planning for lung cancer
Dominic Maes, Jatinder Saini, Jing Zeng, Ramesh Rengan, Tony Wong, Stephen R. Bowen
The cytokinesis-blocked micronucleus assay as a novel biomarker for selection of lung cancer screening participants
Randa A. El-Zein, Carol J. Etzel, Reginald F. Munden
The use of TCP based EUD to rank and compare lung radiotherapy plans: in-silico study to evaluate the correlation between TCP with physical quality indices
Abdulhamid Chaikh, Jacques Balosso

Review Article

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer
Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto
Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement
Hyojin Kim, Jin-Haeng Chung
Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer
Haoran Zhai, Wenzhao Zhong, Xuening Yang, Yi-Long Wu
Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review
Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao
Clinical trials for lung cancer in China
Fei-Yu Niu, Wen-Zhao Zhong, Qing Zhou, Yi-Long Wu
Recurrence after surgery in patients with NSCLC
Hidetaka Uramoto, Fumihiro Tanaka
Prognostic markers in lung cancer: is it ready for prime time?
Chang-Qi Zhu, Ming-Sound Tsao
Potential biomarkers for lung cancer screening
Gabriella Sozzi, Mattia Boeri
Particle therapy in non-small cell lung cancer
Zhongxing Liao, Charles B. Simone II
Computer Aided Nodule Analysis and Risk Yield (CANARY) characterization of adenocarcinoma: radiologic biopsy, risk stratification and future directions
Ryan Clay, Srinivasan Rajagopalan, Ronald Karwoski, Fabien Maldonado, Tobias Peikert, Brian Bartholmai
Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer
Neil K. Taunk, Andreas Rimner, Melissa Culligan, Joseph S. Friedberg, Julie Brahmer, Jamie Chaft
Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors
Suchit H. Patel, Andreas Rimner, Roger B. Cohen
Intraoperative near-infrared imaging of mesothelioma
Gregory Thomas Kennedy, Andrew Newton, Jarrod Predina, Sunil Singhal
BAP1, a tumor suppressor gene driving malignant mesothelioma
Mitchell Cheung, Joseph R. Testa
Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation
Jonathan E. Schoenhals, Steven N. Seyedin, Clark Anderson, Eric D. Brooks, Yun R. Li, Ahmed I. Younes, Sharareh Niknam, Ailin Li, Hampartsoum B. Barsoumian, Maria Angelica Cortez, James W. Welsh
Diagnostic and prognostic biomarkers for malignant mesothelioma: an update
Zhongjian Chen, Giovanni Gaudino, Harvey I. Pass, Michele Carbone, Haining Yang
Immunotherapy for malignant pleural mesothelioma: current status and future directions
Jordan Dozier, Hua Zheng, Prasad S. Adusumilli
Biology and clinical significance of circulating tumor cell subpopulations in lung cancer
Linda O’Flaherty, Harriet Wikman, Klaus Pantel
Routine clinical use of circulating tumor cells for diagnosis of mutations and chromosomal rearrangements in non-small cell lung cancer—ready for prime-time?
Emma Pailler, Vincent Faugeroux, Marianne Oulhen, Cyril Catelain, Françoise Farace
Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer
Sumitra Mohan, Francesca Chemi, Ged Brady
Biophysical technologies for understanding circulating tumor cell biology and metastasis
Derrick W. Su, Jorge Nieva
Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer
Marianna Gallo, Antonella De Luca, Monica Rosaria Maiello, Amelia D’Alessio, Claudia Esposito, Nicoletta Chicchinelli, Laura Forgione, Maria Carmela Piccirillo, Gaetano Rocco, Alessandro Morabito, Gerardo Botti, Nicola Normanno
Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer
Salma K. Jabbour, Abigail T. Berman, Charles B. Simone II

Systematic Review and Meta-analysis

Association of the metformin with the risk of lung cancer: a meta-analysis
Li Wang, Yong Song, Guan-Nan Wu, Dong-Mei Yuan

Editorials

Dulanermin in cancer therapy: Still much to do
Cristina Quintavalle, Gerolama Condorelli

Review Articles

EGFR molecular testing in African-American non-small cell lung cancer patients - a review of discrepant data
Bradley T. Clifford, Pingfu Fu, Nathan A. Pennell, Balazs Halmos, Rom S. Leidner
Copy number gains of FGFR1 and 3q chromosome in squamous cell carcinoma of the lung
Pedro Mendez, Jose Luis Ramirez
Role of HGF/MET axis in resistance of lung cancer to contemporary management
Kanwal Pratap Singh Raghav, Ana Maria Gonzalez-Angulo, George R. Blumenschein Jr
Circulating soluble intercellular adhesion Molecule-1 in lung cancer: a systematic review
Xiaoling Gu, Chunyan Ma, Dongmei Yuan, Yong Song

Onartuzumab plus erlotinib

Targeting MET in NSCLC: looking for a needle in a haystack
Lorenza Landi, Federico Cappuzzo

Review Article on Update on Pathology and Predictive Biomarkers of Lung Cancer

Biology of invasive mucinous adenocarcinoma of the lung
Yoon Jin Cha, Hyo Sup Shim
Immunohistochemistry for predictive biomarkers in non-small cell lung cancer
Mari Mino- Kenudson

Below are the latest Translational Lung Cancer Research articles published online ahead of print publication.

Original Article